This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.
Providing spectacle correction is one of the cornerstones of primary eye care, and myopia controlling spectacles can both correct and control myopia. Here we explore the current myopia controlling spectacle lenses which have or are being commercialized, for which peer-reviewed publications are available – their design, presumed mechanism and comparative efficacy.
Refraction can be challenging in children, and even more so in a complex presentation as for this case. Is this patient a myope or not? When dealing with a complex case of pseudomyopia, antimetropia and latent hyperopia, all in one patient – how should we manage the patient? The answer involves balancing goals to manage ametropia correction, binocular vision function and myopia control.
Pre-myopes can be readily identified, and best practice dictates that we should offer some form of intervention to help delay the onset of myopia. In this case we discuss the features of a pre-myope and an example in a 5 year old patient who satisfies the refractive criteria for pre-myopia, and has a strong family history of myopia.
Esophoria at near is a risk factor for myopia development and progression. Does it need to be managed in an emmetropic patient without symptoms? Is this patient a pre-myope, and how should this factor into management? Read this interesting clinical case, where colleagues discuss whether to intervene or not, and how to potentially manage both myopia risk and binocular vision.
Would you prescribe glasses for a young child with mild myopia? Is myopia control beneficial for a toddler? This case discussion covers whether to treat or monitor, with the research evidence for prescribing as well as clinical considerations for co-management between primary eye care and ophthalmology.
What do you do when your patient doesn’t respond to your low-dose atropine treatment? This case explores the nuances in navigating management when atropine doesn’t work as well as you might expect.
Here we explore an overview of spectacle prescribing for myopia management – from when to use single vision, to progressive and bifocal designs, new myopia control specific designs, and whether to fully or under-correct.
Given their lower efficacy compared to contact lens options, is the additional cost of a progressive or bifocal spectacle lens worth it for myopia control? This discussion in the Myopia Profile Facebook group explores the options, with links to further reading.
Whilst each individual child has their own circumstances and situation to consider when prescribing myopia control, children with astigmatism present a unique set of challenges when selecting the best option for not only slowing down the progression of their axial growth, but also providing them with good vision.
